Crenezumab`s Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune`s Pipeline and Technology Platforms to be presented at the Alzheimer`s Association International Conference in Chicago Lausanne, Switzerland, July 17, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the second Phase 3 (CREAD 2) clinical trial of crenezumab, AC Immune`s anti-Abeta antibody candidate for treatment of Alzheimer`s disease, conducted by its partner Genentech, a member of the Roche Group, has completed global recruitment. Prof. Andrea Pfeifer, CEO of AC Immune, commented: `We are very happy that...
|
